ArticleCureus2026
Predictors of 30-Day Healthcare Utilization After Telemedicine Management of Minimal Traumatic Intracranial Hemorrhage.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Telemedicine protocols for minimal traumatic intracranial hemorrhage (ICH) enable peripheral management without transfer to trauma centers, but post-discharge utilization patterns among these patients remain poorly characterized. This study evaluated factors associated with 30-day readmission and unplanned re-encounter among adult patients managed after implementation of a telemedicine minimal head bleed protocol. Methods A retrospective cohort study was conducted of adult patients with minimal traumatic ICH managed without transfer under a telemedicine protocol at a regional trauma system between July 2021 and December 2023. The primary outcome was 30-day readmission. The secondary outcome was any 30-day unplanned re-encounter. Follow-up was classified as primary care, trauma clinic, surgical subspecialty, or non-surgical subspecialty. Unadjusted comparisons used Fisher's exact testing and Mann-Whitney U testing. Exploratory logistic regression models adjusted for age, sex, and injury severity score (ISS) were performed for each follow-up category. Firth's penalized logistic regression was used as a sensitivity analysis given the limited number of readmission events. Results Among 241 adult patients, 24 (10.0%) experienced a 30-day readmission, and 61 (25.3%) experienced an unplanned re-encounter. Age, sex, and ISS were not significantly associated with either outcome. Any subspecialty follow-up was associated with increased odds of readmission (adjusted odds ratio (OR), 2.73; 95% CI, 1.10-6.77; p = 0.031), confirmed by Firth's penalized regression (OR, 2.72; 95% CI, 1.09-6.55; p = 0.033). Non-surgical subspecialty follow-up demonstrated the strongest association (adjusted OR, 7.15; 95% CI, 1.80-28.50; p = 0.005), while surgical subspecialty follow-up was not significantly associated with readmission (adjusted OR, 1.39; 95% CI, 0.47-4.08; p = 0.551). No measured variable was significantly associated with unplanned re-encounter. Re-encounters were clinically heterogeneous, including recurrent falls and neurologic symptoms. Conclusions Among patients managed via a telemedicine minimal head bleed protocol, age, sex, and ISS were not significantly associated with post-discharge healthcare utilization. Subspecialty follow-up, particularly non-surgical subspecialty care, may serve as a practical marker of post-discharge clinical complexity and could help identify patients for future evaluation of targeted transitional-care strategies. These early findings warrant further studies and validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.